|Articles|June 20, 2019
IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer
Advertisement
Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.
To learn more about their findings, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Generative AI Transforms Clinical Study Report Development
2
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
3
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
4
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
